Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.

Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax

Investors seem perturbed by some reporting about top managers' recent financial moves.

Why Novavax Fell by Over 4% Today

Novavax lost the race to be first with a Covid-19 vaccine, but NVX-CoV2373 is nearing approval. It will boost NVAX stock in 2021.

Why Novavax Stock Is Bound for Massive Gains in 2021

Phase 3 trial delays are pushing NVAX stock down, but the biotech still has a reliable vaccine candidate expected to generate $3.9 billion. The post NVAX Stock Is Worth a Small Position but Vaccine Race Is Tightening appeared first on InvestorPlace.

NVAX Stock Is Worth a Small Position but Vaccine Race Is Tightening

Baxter

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.

Baxter Biopharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

Top executives at U.S. pharmaceutical company Novavax Inc aren't waiting to see how well their COVID-19 vaccine works before they reap the financial rewards.

Novavax bosses cash out for $46 million with COVID-19 vaccine trials still under way

My Best Coronavirus Vaccine Stock for 2021

Exelixis

Vertex Pharmaceuticals

One big biotech and two small biotechs that share a common denominator: Great growth prospects.

3 Top Biotech Picks for 2021

Novavax, Inc. (NASDAQ: NVAX) shares are higher Friday following a coronavirus vaccine supply deal the company announced with the Australian government. Deal Sealed: Novavax, based in Gaithersburg, Maryland, said late Thursday the Australian government has executed a purchase agreement to buy 51 million doses of NVX-CoV2373, the company's coronavirus vaccine candidate, with an option to buy an additional 10 million doses.

Novavax Strikes Another Coronavirus Vaccine Supply Deal: Where Does The Company's Program Stand?

As Covid-19 vaccine leaders took the headlines, NVAX stock slipped into the shadows. However, the former group's setbacks could spell upside opportunity for the latter.

Under-the-Radar Novavax Can Still Make a Splash

Vaxart

2 COVID Stocks That Turned $100,000 Into Well Over $1 Million in 2020

GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax' COVID-19 vaccine candidate. This follows an agreement in principle that was announced in November 2020. NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax' proprietary Matrix-M™ to enhance the immune response.

Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

Beam Global

Blink Charging

Bit Digital, Inc

Cardiff Oncology

Marathon Digital Holdings

Riot Blockchain

Trillium Therapeutics

Biotech, bitcoin, and renewable energy led the way.

The 10 Best-Performing Stocks of 2020

NVAX traded down in December, but there wasn't really any bad news from the company. NVAX did produce some good news with a US/Mexico trial of the company's COVID-19 vaccine getting underway.

Novavax: COVID-19 Trial Underway In The U.S., Results From The U.K. On Tap

It trounced bitcoin in 2020 and has clear potential catalysts on the way.

Forget Bitcoin: This Stock Is a Better Buy

3 Things to Expect from Novavax in 2021

Novavax (NASDAQ: NVAX) saw its stock gain over 3,000% last year. But it could have even more room to run as the market will get only crazier for vaccines this year.

2021 Could Be Novavax's Year

Shares of Novavax could climb by up to 30% if its vaccine is found to be effective, one analyst says.

Novavax Has Covid-19 Vaccine News Coming Out Soon. That Could Be Good for the Stock.

Moderna

The re-opening narrative is dominating activity in the market and governs decisions being made in the business economy, and with good reason. Perhaps never before has so much value been tied to such a singular and distinct dynamic.

Virus Plays in Focus as 2021 Gets in Gear (NASDAQ: NVAX) (OTC US: HALB) (NASDAQ: MRNA)

GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion in each presentation.

Novavax to Participate in Upcoming Conferences

Vaccine specialist Novavax - which is seen as a key player in the Covid-19 vaccine space - saw its stock price decline by about 20% over December. Here are a few possible reasons for the decline.

Why Did Novavax Stock Decline 20% In December?

Investors will soon have data to judge management's big projections.

The Worst Mistake Novavax Investors Can Make Right Now

Altimmune

They're risky but could deliver huge returns in the new year.

3 Coronavirus Stocks Poised to Soar in 2021

These clinical-stage drug developers were unstoppable last year.

3 Healthcare Stocks That Turned $100,000 Into $1 Million in 2020

Co-Diagnostics

Not all of them were COVID-19 vaccine makers.

News for Novavax Stock (NVAX)